Jaguar Health (JAGX) vs Theriva Biologics (TOVX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Theriva Biologics is the larger company by market cap ($10.0 million vs $9.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JAGX | TOVX |
|---|---|---|
| Share price | $4.79 | $0.217 |
| Market cap | $9.32M | $9.96M |
| 1-day change | +5.74% | -4.45% |
| YTD return | — | +8.14% |
| 1-year return | — | -49.53% |
| 5-year return | — | -99.79% |
| P/E ratio (TTM) | — | 0.30 |
| EPS (TTM) | $-4,012.65 | $0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1,260.00 | $0.86 |
| 52-week low | $2.35 | $0.16 |
| Distance from 52-week high | -99.62% | -74.77% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1052.07% |
| Average volume | 2.01M | 525.96K |
| Shares outstanding | 1.95M | 45.89M |
| Employees | 47 | 15 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Jaguar Health
JAGX stock →Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health.
Health Care · Biotechnology: Pharmaceutical Preparations · 47 employees
About Theriva Biologics
TOVX stock →Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 15 employees
JAGX vs TOVX FAQ
Which is bigger, Jaguar Health or Theriva Biologics?
Theriva Biologics (TOVX) is larger, with a market capitalization of $9.96M compared with $9.32M for Jaguar Health (JAGX).
Are Jaguar Health and Theriva Biologics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.